All In Biotech

Drug Trial Radar · NCT06588491

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

KYSA-8: A Phase 2 Open-Label, Single-Arm, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Sep 25, 2024

Primary completion

Jun 25, 2026

Study completion Jun 25, 2026

Sponsor

Lead sponsor
Kyverna TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome

Conditions

  • Stiff-Person Syndrome
  • SPS

Interventions

  • Standard lymphodepletion regimenBiological

    Standard lymphodepletion regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate efficacy of KYV-101Time frame: Up to 12 months
  2. To evaluate the safety of KYV-101Time frame: Up to 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Mayo Clinic

    Rochester, Minnesota

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.